Lung cancer drug Imfinzi improves overall survival at interim analysis in phase III CASPIAN trial

Image: Lung cancer drug Imfinzi has improved overall survival at interim analysis in the phase III CASPIAN trial. Photo: courtesy of AstraZeneca.